CADL
Candel Therapeutics, Inc.
Biotechnology · Healthcare · United States
8.33
close · 2026-10-30
value
80
cheaper than peers80
quality
19
stronger fundamentals19
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | -6.1% | 78 |
| earnings yield, 3 years ago | -7.8% | 77 |
| earnings yield, latest year | -8.6% | 77 |
| cash flow yield, 1 year ago | -4.2% | 77 |
| cash flow yield, 2 years ago | -5.4% | 68 |
| cash flow yield, 3 years ago | -5.1% | 68 |
| earnings yield, 2 years ago | -15.7% | 65 |
| earnings yield, 1 year ago | -20.9% | 55 |
| price to book | 5.03× | 29 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -81.8% | 35 |
| debt to equity | 39.3% | 18 |
3 of 4 measures available
Facts
| market cap | $637M |
| free cash flow | -$35.8M |
| employees | 55 |
| first trade | 2021-07-27 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.72 | -1.74 | -1.31 | -0.65 |
| free cash flow | -$38.9M | -$27.0M | -$34.7M | -$32.7M |
| net income | -$38.2M | -$55.2M | -$37.9M | -$18.8M |
| revenue | $0 | $0 | $0 | $125,000 |
| unusual items | $8.2M | -$20.8M | $966,000 | $16.4M |